{"ModuleTitle": "Company Description", "CompanyName": "ACADIA Pharmaceuticals Inc.", "Symbol": "ACAD", "Address": "3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO, California, 92130, United States of America", "Phone": "858-558-2871", "Industry": "Major Pharmaceuticals", "Sector": "Health Care", "Region": "North America", "CompanyDescription": "We are a biopharmaceutical company focused on the development and\r\ncommercialization of innovative medicines that address unmet medical needs in\r\ncentral nervous system (CNS) disorders. We have a portfolio of product\r\nopportunities led by our novel drug, NUPLAZID (pimavanserin), which was approved\r\nby the U.S. Food and Drug Administration (FDA) in April 2016 for the treatment\r\nof hallucinations and delusions associated with Parkinson's disease psychosis,\r\nor PD Psychosis, and is the first and only drug approved in the United States\r\nfor this condition. NUPLAZID is a selective serotonin inverse\r\nagonist/antagonist, preferentially targeting 5-HT2A receptors with no\r\nappreciable affinity for dopaminergic, histaminergic, or muscarinic receptors.\r\nThrough this novel mechanism, NUPLAZID demonstrated significant efficacy in\r\nreducing the hallucinations and delusions associated with PD Psychosis without\r\nnegatively impacting motor function in our Phase 3 pivotal trial.&nbsp;&nbsp;... <a href=\"http://secfilings.nasdaq.com/edgar_conv_html%2f2020%2f02%2f27%2f0001564590-20-006889.html#FIS_BUSINESS\" target=\"_blank\">More</a> ...&nbsp;&nbsp;\r\n", "KeyExecutives": [{"name": "Elena H. Ridloff", "title": "EVP, Chief Financial & Accounting Officer"}, {"name": "Eliseo Oreste Salinas", "title": "Chief Scientific Officer & Senior Vice President"}, {"name": "Mark Schneyer", "title": "Chief Business Officer & SVP-Business Development"}, {"name": "Ponni Subbiah", "title": "Chief Medical Officer & Senior Vice President"}, {"name": "Stephen R. Davis", "title": "Chief Executive Officer & Director"}], "Number_of_employees": [], "Subsidiaries": ["NO INFO"]}